Sight Sciences, Inc.
NASDAQ:SGHTMedical - Devices
+$0.15 today
- Market cap
- $598.59M
- Beta
- 2.40
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$0.69
Volume 0.34M
Average 0.25M
SGHT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Sight Sciences, Inc.NASDAQ: SGHT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q1 FY2026 capital expenditures was -$60K, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$284K. Over 3 fiscal years it compounded at -38.6% a year.
Context
- Capital expenditures amounted to 0.3% of revenue in FY2025, down 0.2 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near -$60K or moves back toward the trailing-twelve-month quarterly average of -$71K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (224K) USD
- Year-over-year change
- +41.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (224K) | +41.8% |
| FY2024 | 2024-12-31 | (385K) | +51.3% |
| FY2023 | 2023-12-31 | (791K) | +18.5% |
| FY2022 | 2022-12-31 | (970K) | -19.3% |
| FY2021 | 2021-12-31 | (813K) | — |
Capital Expenditures vs competitors
How SGHT compares with its peers on the latest reported figures
- SGHT's LTM Mar 2026 capital expenditures of $284K is the smallest of the 7 companies compared; the peer median is $12.99M.
- Its year-over-year change of +6.0% is the 3rd highest of 6, against a peer median of +1.8%.
- Capital expenditures amounts to 0.4% of revenue for SGHT, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $582.3M | -0.1% | -3.8% | 5.3% | |
| LTM Jun 2026 | $408.39M | +1.8% | +14.0% | 3.8% | |
| LTM Mar 2026 | $14.74M | +396.9% | +47.9% | 28.3% | |
| LTM Jun 2026 | $11.25M | +78.5% | -36.7% | 1.8% | |
| LTM Mar 2026 | $926K | -97.6% | -47.9% | 0.3% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $789K | — | — | — |
| LTM Mar 2026 | $284K | +6.0% | -38.6% | 0.4% | |
| Peer median (excluding SGHT) | $12.99M | +1.8% | -3.8% | 3.8% | |
Competitors are the stored peer set for SGHT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (62.96M) | (86.24M) | (55.55M) | (51.51M) | (38.43M) |
| Depreciation & Amortization | 632K | 710K | 614K | 712K | 487K |
| Deferred Income Tax | 7.76M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.08M | 12.96M | 14.58M | 17.08M | 13.05M |
| Change in Working Capital | (4.33M) | (5.7M) | (9.13M) | 9M | (6.4M) |
| Accounts Receivables | (3.69M) | (6.84M) | 661K | 3.55M | 912K |
| Inventory | (1.31M) | (3.25M) | (2.16M) | 1.63M | (1.44M) |
| Accounts Payables | 1.17M | (694K) | (883K) | 336K | (348K) |
| Other Working Capital | (486K) | 5.09M | (6.76M) | 3.49M | (5.52M) |
| Other Non-Cash Items | 1.27M | 2.3M | 2.3M | 2.37M | 1.59M |
| Operating Cash Flow | (52.54M) | (75.97M) | (47.18M) | (22.35M) | (29.69M) |
| Capital Expenditures | (813K) | (970K) | (791K) | (385K) | (224K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (813K) | (970K) | (791K) | (385K) | (224K) |
| Debt Repayment | 0 | 0 | 0 | 4.15M | 0 |
| Common Stock Issued | 256.68M | 1.25M | 1.33M | 1.07M | 1.85M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.15M) | 1.25M | (224K) | (261K) | (58K) |
| Financing Cash Flow | 252.53M | 1.25M | 1.1M | 4.96M | 1.79M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 199.18M | (75.69M) | (46.87M) | (17.77M) | (28.13M) |
| Free Cash Flow | (53.35M) | (76.94M) | (47.98M) | (22.74M) | (29.92M) |
Sight Sciences, Inc.
NASDAQ:SGHT
Intrinsic Alpha fair value
Locked
Current Price
$10.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.